 <h1>Kynamro Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>mipomersen</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about mipomersen. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Kynamro.</p><h2>In Summary</h2><p><b>Common side effects of Kynamro include:</b> bleeding at injection site, fatigue, flu-like symptoms, hematoma at injection site, increased serum alanine aminotransferase, lipomatosis, rash at injection site, arthralgia, fever, increased serum aspartate aminotransferase, injection site reaction, myalgia, nausea, chills, induration at injection site, inflammation at injection site, injection-site pigmentation changes, swelling at injection site, erythema at injection site, malaise, pain at injection site, and tenderness at injection site. <b>Other side effects include:</b> abnormal hepatic function tests, and vomiting.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to mipomersen: subcutaneous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Subcutaneous route (Solution)</p><p>Mipomersen sodium can cause elevations in transaminases and also increases hepatic fat (with or without concomitant increases in transaminases). Hepatic steatosis is a risk factor for advanced liver disease, including steatohepatitis and cirrhosis. Measure ALT, AST, alkaline phosphatase, and total bilirubin prior to initiation. Measure ALT and AST regularly. If ALT or AST are 3 times the ULN or greater, interrupt therapy. If clinically significant liver toxicity occurs, discontinue therapy. Mipomersen sodium is available only through a restricted program called the Kynamro® REMS. Prescribe mipomersen sodium only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, mipomersen (the active ingredient contained in Kynamro) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking mipomersen:</p><p>
<i>More common</i>
</p><ul>
<li>Chills</li>
<li>cough</li>
<li>dark urine</li>
<li>diarrhea</li>
<li>fever</li>
<li>general feeling of discomfort or illness</li>
<li>headache</li>
<li>joint pain</li>
<li>light-colored stools</li>
<li>loss of appetite</li>
<li>muscle aches and pains</li>
<li>nausea and vomiting</li>
<li>runny nose</li>
<li>shivering</li>
<li>sore throat</li>
<li>sweating</li>
<li>trouble sleeping</li>
<li>unusual tiredness or weakness</li>
<li>upper right abdominal or stomach pain</li>
<li>vomiting</li>
<li>yellow eyes and skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Arm, back, or jaw pain</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>chest pain or discomfort</li>
<li>chest tightness or heaviness</li>
<li>fast or irregular heartbeat</li>
<li>irregular, pounding, or racing heartbeat or pulse</li>
<li>rapid weight gain</li>
<li>shortness of breath</li>
<li>sweating</li>
<li>tingling of the hands or feet</li>
<li>unusual weight gain or loss</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of mipomersen may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>pain in the arms or legs</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to mipomersen: subcutaneous solution</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension (7%), angina pectoris (4%), palpitations (3%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): [All injection site reactions (84%)], erythema (59%), pain (56%), hematoma (32%), pruritus (29%), swelling (18%), discoloration (17%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (14%)</p>
<p><b>Common</b> (1% to 10%): Vomiting (4%), abdominal pain (3%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Alanine aminotransferase (ALT) increased (10%)</p>
<p><b>Common</b> (1% to 10%): Hepatic steatosis (7%), aspartate aminotransferase (AST) increased (6%), liver function test abnormal (5%), hepatic enzyme increased (3%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Rare</b> (less than 0.1%): One case of hypersensitivity with angioedema was reported<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Proteinuria (9%), peripheral edema (5%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Pain in extremity (7%), musculoskeletal pain (4%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Fatigue (15%), headache (12%)</p>
<p><b>Common</b> (1% to 10%): Pyrexia (8%), chills (6%)<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Neoplasms [benign and malignant] (4%)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia (3%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Rare</b> (less than 0.1%): One case of glomerular nephritis was reported<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Kynamro (mipomersen)." Genzyme Corporation, Cambridge, MA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Kynamro (mipomersen)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: miscellaneous antihyperlipidemic agents</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Kynamro &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>High Cholesterol</li>
<li>High Cholesterol, Familial Homozygous</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to mipomersen: subcutaneous solution</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension (7%), angina pectoris (4%), palpitations (3%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): [All injection site reactions (84%)], erythema (59%), pain (56%), hematoma (32%), pruritus (29%), swelling (18%), discoloration (17%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (14%)</p><p><b>Common</b> (1% to 10%): Vomiting (4%), abdominal pain (3%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Alanine aminotransferase (ALT) increased (10%)</p><p><b>Common</b> (1% to 10%): Hepatic steatosis (7%), aspartate aminotransferase (AST) increased (6%), liver function test abnormal (5%), hepatic enzyme increased (3%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Rare</b> (less than 0.1%): One case of hypersensitivity with angioedema was reported<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Proteinuria (9%), peripheral edema (5%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Pain in extremity (7%), musculoskeletal pain (4%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Fatigue (15%), headache (12%)</p><p><b>Common</b> (1% to 10%): Pyrexia (8%), chills (6%)<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Neoplasms [benign and malignant] (4%)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia (3%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Rare</b> (less than 0.1%): One case of glomerular nephritis was reported<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Kynamro (mipomersen)." Genzyme Corporation, Cambridge, MA. </p><h2>More about Kynamro (mipomersen)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: miscellaneous antihyperlipidemic agents</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Kynamro &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>High Cholesterol</li>
<li>High Cholesterol, Familial Homozygous</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>